US20070197485A1 - Therapy and Use of Compounds in Therapy - Google Patents
Therapy and Use of Compounds in Therapy Download PDFInfo
- Publication number
- US20070197485A1 US20070197485A1 US11/627,183 US62718307A US2007197485A1 US 20070197485 A1 US20070197485 A1 US 20070197485A1 US 62718307 A US62718307 A US 62718307A US 2007197485 A1 US2007197485 A1 US 2007197485A1
- Authority
- US
- United States
- Prior art keywords
- patients
- ursodeoxycholic acid
- cachexia
- endotoxin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- the present invention relates to therapy and the use of agents in the therapy of cachexia and wasting syndromes due to diseases other than congestive heart failure.
- Cachexia occurs in a number of other chronic diseases, like liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis.
- Cachexia and weight loss are linked to inflammatory processes and they are linked to increased mortality and/or morbidity. Cytokine activation is a potential causal mechanism for the development of cachexia also in these other diseases.
- the patient has cachexia, as characterised by loss of muscle, fat, and or bone tissue.
- the patient has experienced weight loss >7.5%.
- the compound is able to substantially reduce the biological activity of endotoxin (lipopolysaccharide) such that the endotoxin mediated production of inflammatory cytokines in the circulating blood is reduced.
- endotoxin lipopolysaccharide
- bile acid we include all naturally occurring bile acids whether from man or from another animal. Also is included bile acids which are synthetic or semi-synthetic derivatives of naturally occurring bile acids. Of course, all bile acids including those that are “naturally occurring” may be synthesised chemically.
- Bile acids are available from Falk Pharma. GmbH and are described, for example, in WP96/17859, DE29717252 and WO98/05339.
- Bile acids for use in the method of the invention include, but are not limited to, chemodeoxycholic acid (3d,7 ⁇ -dihydroxy-5-cholan-24-oic-acid), arsodeoxycholic acid (3 ⁇ ,7-dihydroxy-5-cholan-24-oic acid), dehydrocholic acid (3,7,12-trioxo-5-cholan-24-oic acid), cholic acid and deoxycholic acid.
- the bile acid is a bile acid which is able to form micelles.
- the bile acid is able to form a micelle around an endotoxin (lipopolysacharide molecule).
- the bile acid is able to bind to endotoxin (lipopolysaccharide) molecules and substantially reduce the available endotoxin in the patient.
- the bile acid is able to substantially reduce the biological activity of endotoxin (lipopolysaccharide) such that the endotoxin has a substantially reduced effect on the liver or does not reach the liver in a substantially active form.
- the bile acid is any one of ursodeoxycholic acid, chemodeoxycholic acid, dehydrocholic acid, cholic acid and deoxycholic acid.
- the bile acid is ursodeoxycholic acid.
- Ursodeoxycholic acid has for many years been proposed to be useful also in patients with cholestatic disease, and particularly in patients with primary biliary cirrhosis, a chronic cholestatic liver disease (Lindor et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996, 110:1515-1518).
- UDCA is used in other cholestatic disorders like primary sclerosing cholangitis (Beuerset al: Therapie der autoimmunen Hepatitis, primar biliaren Zirrhose und primär sklerosierenden Cholangitis. Konsensus der Deutschen Deutschen für Verdauungsund Stoff monocytekrank pulp. Z. Gastroenterologie 1997; 35:1041-1049) or benign cholestasis of pregnancy (Palma et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997, 27:1022-1028). Regarding its mode of action, most authorities regard increased bile flow and a reduced hepatocellular insult as a result of improved bile flow and altered bile salt patterns as the main modes of UDCA action in chronic cholestatic liver diseases.
- ursodeoxycholic acid can not be considered a treatment with proven efficacy in patients with liver disease.
- ursodeoxycholic acid should be specifically given to patients with cachexia due to liver cirrhosis.
- ursodeoxycholic acid should be specifically given to patients with alcoholic liver cirrhosis. In fact, such patients were specifically excluded from studies.
- endotoxaemia occurs in a number of patients with liver cirrhosis. It is not known, whether endotoxin (LPS) levels are particularly raised in patients with cachexia due to liver cirrhosis.
- LPS endotoxin
- liver cirrhosis occurs in 30 to 60% of patients with liver cirrhosis, and the survival of patients with cachexia in liver cirrhosis is impaired.
- Pralauth et al ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997, 16:43-55.
- BCM body cell mass
- Bile acids can protect the liver against endotoxin action in obstructive jaundice when patients undergo surgery (Greve et al. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study. Hepatology Oct. 1, 1989; 10(4):454-458). With regards to monocyte generated cytokine production in response to LPS, in this study deoxycholic acid was the most effective, chenodeoxycholic acid was less effective and ursodeoxycholic acid was ineffective in the concentrations used. Bile acids did not inactivate endotoxin as measured in a chromogenic Limulus amebocyte lysate assay. In these studies patients with non-cholestatic or alcoholic aetiology were not considered, and there was no data or discussion of cachexia and weight loss.
- ursodeoxycholic acid ursodeoxycholic acid
- cytokine levels are poor in these studies, and the cellular effects of ursodeoxycholic acid (UDCA) are conflicting.
- ursodeoxycholic acid should be given in patients with weight loss, i.e. cachexia, in patients with liver disease. It has never been proposed that ursodeoxycholic acid (UDCA) could prevent or reverse weight loss, i.e. cachexia, in patients with liver disease. Additionally, it has never been proposed that ursodeoxycholic acid (UDCA) could prevent or reverse weight loss, i.e. cachexia, in patients with chronic obstructive pulmonary disease, chronic renal failure, diabetes, rheumatoid arthritis.
- weight loss i.e. cachexia
- UDCA ursodeoxycholic acid
- FIG. 1 is a graphical representation showing levels of soluble CD14, TNF- ⁇ and endotoxin in a sampling of patients;
- FIG. 2 is graphical representation showing the concentration of endotoxin in CHF patients before and after treatment
- FIG. 3 is a graphical representation showing that Lipoprotein-free serum lacks LPS-neutralizing activity
- FIG. 4 is a graphical representation showing that certain lipoproteins inhibit LPS-induced TNF- ⁇ release
- FIG. 5 is a graphical representation showing reduction of TNF- ⁇ release upon increased concentration of high-density lipo proteins in a whole blood sample
- FIG. 6 is a graphical representation showing that low-density lipoproteins show enhanced neutralization capacity in the presence of increased LBP-concentrations
- FIG. 7 is a graphical representation showing that addition of LBP to a lipoprotein containing serum reduced LPS-mediated TNF- ⁇ production
- FIG. 8 is a table showing LPS neutralization by UDCA in whole blood of four healthy patients.
- FIG. 9 is a table showing LPS neutralization by UDCA in whole blood of patient 1;
- FIG. 10 is a table showing LPS neutralization by UDCA in whole blood of patient 2;
- FIG. 11 is a table showing LPS neutralization by UDCA in whole blood of patient 3;
- FIG. 12 is a table showing LPS neutralization by UDCA in whole blood of patient 4.
- Heparinized whole blood was diluted 1:10 with medium ⁇ LPS (50 ⁇ g/ml), ⁇ BPi (1 ⁇ g/ml), and ⁇ UDCA (1 ⁇ g/ml-1 mg/ml) according to the manufacturer's recommendation (Milenia whole blood assay; DPC Biermann, Bad Nauheim, Germany) and incubated for 4 hours at 37° C. In the supernatant, we assessed concentrations of TNF and IL-6 using the semiautomated Immulite system (DPC-Biermann, Bad Nauheim, Germany).
- UDCA reduced LPS-stimulated TNF and IL6 production by 42% and 13%, respectively, ethanol 0.1% alone on average only 9% for TNF and IL6 production increased by 18% for ethanol alone).
- BPi (1 ug/ml) reduced significantly the spontaneous production of TNF and IL6 of whole blood of patients with cachexia due to liver cirrhosis.
- TNF and IL6 levels were lowered by at least 5 pg/mi or towards non-detectability, and only in 2 cases TNF and IL6 levels remained stable (p ⁇ 0.05 for changes).
- Heparinized whole blood was diluted 1:10 with medium ⁇ LPS (50 pg/ml), ⁇ BPI (1 ug/ml), and ⁇ UDCA (1 ug/ml-1 mg/ml) according to the manufacturer's recommendation (Milenia whole blood assay; DPC Biermann, Bad Nauheim, Germany) and incubated for 4 hours at 37° C.
- concentrations of TNF and IL-6 using the semiautomated Immulite system (DPC-Biermann, Bad Nauheim, Germany).
- endotoxin LPS
- sCD14 soluble CD14
- Soluble CD14 was measured by ELISA (R&D Systems). The majority of patients had a BCM of ⁇ 35% of body weight (mean standard deviation: 25 ⁇ 7%, median 33%, range 11.8-41.9%).
- Plasma sCDI4 levels were significantly increased in patients (mean ⁇ standard deviation: 4045 ⁇ 623 pg/ml, median 3920 pg/ml, range 2960-5460 pg/ml) compared to sCD14 levels of healthy individuals (mean: 2714 pg/ml, upper limit of normal 3711 pg/ml, as published in Anker et al., Am. J Cardiol 1997; 79;1426-1430).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/627,183 US20070197485A1 (en) | 1999-03-09 | 2007-01-25 | Therapy and Use of Compounds in Therapy |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9905314.2A GB9905314D0 (en) | 1999-03-09 | 1999-03-09 | Therapy and use of compounds in therapy (2) |
GBGB9905307.6A GB9905307D0 (en) | 1999-03-09 | 1999-03-09 | Therapy and use of compounds in therapy |
GBGB9905300.1A GB9905300D0 (en) | 1999-03-09 | 1999-03-09 | Therapy and use of agents in therapy |
GB9905310.0 | 1999-03-09 | ||
GB9905300.1 | 1999-03-09 | ||
GB9905314.2 | 1999-03-09 | ||
GBGB9905315.9A GB9905315D0 (en) | 1999-03-09 | 1999-03-09 | Therapy and use of compounds in therapy |
GB9905307.6 | 1999-03-09 | ||
GB9905315.9 | 1999-03-09 | ||
GBGB9905310.0A GB9905310D0 (en) | 1999-03-09 | 1999-03-09 | Therapy and use of compounds in therapy (4) |
PCT/EP2000/002062 WO2000053165A2 (en) | 1999-03-09 | 2000-03-09 | Use of inhibitors of endotoxin for the treatment of chachexia |
US1945202A | 2002-02-25 | 2002-02-25 | |
US11/627,183 US20070197485A1 (en) | 1999-03-09 | 2007-01-25 | Therapy and Use of Compounds in Therapy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/002062 Continuation WO2000053165A2 (en) | 1999-03-09 | 2000-03-09 | Use of inhibitors of endotoxin for the treatment of chachexia |
US1945202A Continuation | 1999-03-09 | 2002-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070197485A1 true US20070197485A1 (en) | 2007-08-23 |
Family
ID=27517498
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/627,183 Abandoned US20070197485A1 (en) | 1999-03-09 | 2007-01-25 | Therapy and Use of Compounds in Therapy |
US12/187,169 Abandoned US20090197851A1 (en) | 1999-03-09 | 2008-08-06 | Therapy and use of compounds in therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/187,169 Abandoned US20090197851A1 (en) | 1999-03-09 | 2008-08-06 | Therapy and use of compounds in therapy |
Country Status (10)
Country | Link |
---|---|
US (2) | US20070197485A1 (de) |
EP (2) | EP1212064A2 (de) |
AT (1) | ATE365043T1 (de) |
AU (2) | AU3809900A (de) |
CY (1) | CY1107436T1 (de) |
DE (1) | DE60035262T2 (de) |
DK (1) | DK1158989T3 (de) |
ES (1) | ES2288847T3 (de) |
PT (1) | PT1158989E (de) |
WO (2) | WO2000053165A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115137733A (zh) * | 2022-08-24 | 2022-10-04 | 吉林大学 | 熊去氧胆酸在制备mcr-3酶抑制剂中的应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1302206A1 (de) * | 2001-10-11 | 2003-04-16 | Universitair Medisch Centrum Utrecht | Verfahren und Mittel zur Verwendung des adventitial Toll-like-Rezeptors |
US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
ATE406172T1 (de) * | 2003-03-21 | 2008-09-15 | Bridge Biores Ltd | Verwendung von löslichem cd14 zur behandlung von erkrankungen |
US7883701B2 (en) * | 2003-12-19 | 2011-02-08 | Wisconsin Alumni Research Foundation | Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract |
RU2362570C2 (ru) * | 2004-06-02 | 2009-07-27 | Куреха Корпорейшн | Средство для устранения фактора циркуляторной дисфункции |
TWI487535B (zh) | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體3(toll like receptor3)拮抗劑,方法及用途 |
EP1741440A1 (de) * | 2005-07-08 | 2007-01-10 | Mellitus S.L. | Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen |
DK1945820T3 (da) | 2005-10-27 | 2013-11-11 | Janssen Biotech Inc | Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser |
KR100785656B1 (ko) * | 2007-05-14 | 2007-12-17 | 재단법인서울대학교산학협력재단 | 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체 |
EP2208497A1 (de) * | 2009-01-15 | 2010-07-21 | Charité-Universitätsmedizin Berlin (Charité) | Verwendung von Ursodesoxycholsäure (UDCA) zum Verbessern des allgemeinen Gesundheitszustands eines Tumorpatienten |
CN115120681A (zh) * | 2022-07-19 | 2022-09-30 | 浙江长三角聚农科技开发有限公司 | 竹笋生物炭在制备治疗糖尿病及其并发症药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
US4898879A (en) * | 1981-06-29 | 1990-02-06 | Baxter International Inc. | Nurtitional composition for management of hepatic failure |
US5087453A (en) * | 1990-11-01 | 1992-02-11 | Otsuka Pharmaceutical Co., Ltd. | Method for the treatment of bacterial caused weight loss and/or hypoglycemia |
US5639744A (en) * | 1994-04-06 | 1997-06-17 | Alfa Wassermann S.P.A. | Bile acids derivatives useful in the therapy of the biliary calculosis from cholesterol and of the pathologies caused by cholestasis |
US5869265A (en) * | 1993-12-29 | 1999-02-09 | Wake Forest University | Ileal bile acid transporter compositions and methods |
US6251884B1 (en) * | 1995-11-21 | 2001-06-26 | Children's Hospital Medical Center | Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674855A (en) * | 1992-08-12 | 1997-10-07 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
-
2000
- 2000-03-09 DK DK00916915T patent/DK1158989T3/da active
- 2000-03-09 EP EP00920504A patent/EP1212064A2/de not_active Withdrawn
- 2000-03-09 DE DE60035262T patent/DE60035262T2/de not_active Expired - Fee Related
- 2000-03-09 PT PT00916915T patent/PT1158989E/pt unknown
- 2000-03-09 ES ES00916915T patent/ES2288847T3/es not_active Expired - Lifetime
- 2000-03-09 WO PCT/EP2000/002062 patent/WO2000053165A2/en active IP Right Grant
- 2000-03-09 AU AU38099/00A patent/AU3809900A/en not_active Abandoned
- 2000-03-09 WO PCT/EP2000/002299 patent/WO2000053224A2/en active Application Filing
- 2000-03-09 EP EP00916915A patent/EP1158989B1/de not_active Expired - Lifetime
- 2000-03-09 AT AT00916915T patent/ATE365043T1/de not_active IP Right Cessation
- 2000-03-09 AU AU41056/00A patent/AU4105600A/en not_active Abandoned
-
2007
- 2007-01-25 US US11/627,183 patent/US20070197485A1/en not_active Abandoned
- 2007-09-14 CY CY20071101218T patent/CY1107436T1/el unknown
-
2008
- 2008-08-06 US US12/187,169 patent/US20090197851A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
US4898879A (en) * | 1981-06-29 | 1990-02-06 | Baxter International Inc. | Nurtitional composition for management of hepatic failure |
US5087453A (en) * | 1990-11-01 | 1992-02-11 | Otsuka Pharmaceutical Co., Ltd. | Method for the treatment of bacterial caused weight loss and/or hypoglycemia |
US5869265A (en) * | 1993-12-29 | 1999-02-09 | Wake Forest University | Ileal bile acid transporter compositions and methods |
US5639744A (en) * | 1994-04-06 | 1997-06-17 | Alfa Wassermann S.P.A. | Bile acids derivatives useful in the therapy of the biliary calculosis from cholesterol and of the pathologies caused by cholestasis |
US6251884B1 (en) * | 1995-11-21 | 2001-06-26 | Children's Hospital Medical Center | Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115137733A (zh) * | 2022-08-24 | 2022-10-04 | 吉林大学 | 熊去氧胆酸在制备mcr-3酶抑制剂中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2000053224A2 (en) | 2000-09-14 |
WO2000053224A3 (en) | 2002-04-04 |
PT1158989E (pt) | 2007-10-01 |
AU4105600A (en) | 2000-09-28 |
EP1212064A2 (de) | 2002-06-12 |
WO2000053165A3 (en) | 2001-04-12 |
AU3809900A (en) | 2000-09-28 |
ES2288847T3 (es) | 2008-02-01 |
WO2000053165A2 (en) | 2000-09-14 |
ATE365043T1 (de) | 2007-07-15 |
DK1158989T3 (da) | 2007-10-22 |
US20090197851A1 (en) | 2009-08-06 |
CY1107436T1 (el) | 2012-12-19 |
DE60035262D1 (de) | 2007-08-02 |
DE60035262T2 (de) | 2008-02-21 |
EP1158989A2 (de) | 2001-12-05 |
EP1158989B1 (de) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070197485A1 (en) | Therapy and Use of Compounds in Therapy | |
Trauner et al. | The nonsteroidal farnesoid X receptor agonist cilofexor (GS‐9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis | |
EP3054940B1 (de) | Zusammensetzungen und verfahren zur behandlung nichtalkoholischer steatohepatitis | |
Cerquaglia et al. | Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update | |
Rosenne et al. | In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins | |
Tiessen et al. | Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial | |
JP2021063088A (ja) | 非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法 | |
Camilleri et al. | Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea | |
Alawad et al. | FXR agonists: from bench to bedside, a guide for clinicians | |
Portincasa et al. | Primary sclerosing cholangitis: updates in diagnosis and therapy | |
JPH10504037A (ja) | 内毒素関連疾患の予防および治療に用いられる方法および組成物 | |
CN109195594A (zh) | 肝内胆汁淤积性疾病的治疗 | |
JP6915050B2 (ja) | Fxrアゴニストの新規のレジーム | |
De Sanctis et al. | Review and recommendations on management of adult female thalassemia patients with hypogonadism based on literature review and experience of ICET-A network specialists | |
Tziomalos et al. | Colesevelam: a new and improved bile acid sequestrant? | |
Loria et al. | Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects | |
Marks et al. | Effects of ursodiol or ibuprofen on contraction of gallbladder and bile among obese patients during weight loss | |
US6348495B1 (en) | Method for treating celiac disease | |
Nakagaki et al. | Effect of female sex hormones on lithogenicity of bile | |
Cagnacci et al. | The effect of hormonal contraceptives on metabolism | |
Lee et al. | Pathogenesis and treatment of gallbladder stone | |
Marks et al. | Roles of deoxycholate and arachidonate in pathogenesis of cholesterol gallstones in obese patients during rapid loss of weight | |
Talamini et al. | Gallstone dissolution | |
Schnyder-Candrian et al. | Hepatic steatosis in the absence of tumor necrosis factor in mice | |
Ellsworth et al. | Evaluation of a new triphasic oral contraceptive in private practice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |